FLT3 mutation
Vanflyta Approved for Newly Diagnosed Acute Myeloid Leukemia
The FDA approved quizartinib (Vanflyta, Daiichi Sankyo) with standard cytarabine and anthracycline induction and ...
JULY 24, 2023
Novartis’ Leukemia Drug Granted Priority Review
The drug was granted priority review to treat newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and ...
NOVEMBER 18, 2016
Midostaurin Provides Survival Benefit in Newly Diagnosed AML
Orlando, Fla.—Based on an overall survival (OS) benefit in a Phase III trial, midostaurin was declared a ...
JANUARY 15, 2016
Load more